Detalhe da pesquisa
1.
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Ann Oncol
; 31(8): 1001-1010, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32416251
2.
Keratoconus: age of onset and natural history.
Optom Vis Sci
; 74(3): 147-51, 1997 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-9159804